Skip to main content
SpringerLink
Log in

Quality of Life in Head and Neck Cancer Patients

  • Chapter
  • First Online:
Head and Neck Cancer

Abstract

Quality of life (QOL) is a measure of an individual’s overall well-being. It is a patient-reported outcome that can only be accurately assessed by the individual. It is measured using standardized instruments with known validity and reliability. These include multidimensional questionnaires or single-item indices. Specialized QOL instruments are available for certain diseases, symptoms, or treatments. A related concept is health utility, which quantifies not only health but its value to the individual under conditions of uncertainty. Results for both QOL and utility instruments are most useful when reported in the context of their significance—both statistical (probability of error) and clinical (whether magnitude is meaningful to patients).

Each individual conceptualizes QOL in a personal way. When QOL is an outcome of a clinical trial, prospective measurement at multiple time points is preferred. However, “baseline QOL” is measured after cancer diagnosis and does not reflect “healthy” QOL. Additionally, individuals may reconceptualize QOL over time, so concurrent comparative cohorts are needed to interpret QOL changes over time. Missing data is especially important in QOL research, because healthier patients are more likely to comply with assessments.

Specific concerns such as xerostomia, pain, dysphagia, and speech disruption often dominate the posttreatment QOL experience of head and neck cancer (HNC) patients. Instruments designed specifically for HNC will best discriminate between patients and respond to change over time. Among a number of HNC-specific QOL instruments, the most commonly used are the EORTC QLQ-C30/HN35, FACT-H&N, and UW-QOL. Few phase III randomized controlled trials in HNC have yet reported QOL results. The use of intensity-modulated radiation therapy to reduce parotid dose lessens xerostomia and improves QOL; certain supportive care initiatives improve QOL during HNC treatment. Additionally, baseline QOL is among the strongest prognostic factors in HNC and is an obvious candidate for stratification in future clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Karnofsky DA, Abelmann WH, Craver LF, et al. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer. 1948;1(4):634–56.

    Article  Google Scholar 

  2. Rehabilitation after cardiovascular diseases, with special emphasis on developing countries. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1993;831:1–122.

    Google Scholar 

  3. National Election Studies, 1964: Pre/Post Election Study. In: Political Behavior Program tSRCotIoSR, editor. Ann Arbor: University of Michigan, Center for Political Studies; 1999.

    Google Scholar 

  4. Bennet KJ, Torrance G. Measuring health state preferences and utilities: rating scale, time trade-off, and standard gamble techniques. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven; 1996. p. 259.

    Google Scholar 

  5. Guidance for industry: Patient-reported outcome measures: use in medical product development to support labeling claims.2009; http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM193282.pdf. Accessed January 5, 2015.

  6. Schoemaker PJH. The expected utility model: its variants, purposes and limitations. J Econ Lit. 1982;20:529–63.

    Google Scholar 

  7. Leppo NE. The first ten years of the World Health Organization. Minn Med. 1958;41(8):577–83.

    CAS  PubMed  Google Scholar 

  8. Schwartz S, McDowell J, Yueh B. Numeracy and the shortcomings of utility assessment in head and neck cancer patients. Head Neck. 2004;26(5):401–7.

    Article  PubMed  Google Scholar 

  9. Martino R, Ringash J. Evaluation of quality of life and organ function in head and neck squamous cell carcinoma. Hematol Oncol Clin of North Am. 2008;22(6):1239–56.

    Article  Google Scholar 

  10. Ringash J, Bernstein L, Cella D, et al. Outcomes toolbox for head and neck cancer research. Head Neck. 2015;37:425–39.

    Article  PubMed  Google Scholar 

  11. Pusic A, Liu J, Chen C, et al. A systematic review of patient-reported outcome measures in head and neck cancer surgery. Otolaryngology Head Neck Surg. 2007;136(4):525–35.

    Article  Google Scholar 

  12. Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983;17(2):197–210.

    Article  CAS  PubMed  Google Scholar 

  13. Hjermstad MJ. Assessment and classification of cancer pain. Curr Opin Support Pall Care. 2009;3(1):24–30.

    Article  Google Scholar 

  14. Dirix P, Nuyts S, Van den Bogaert W. Radiation-induced xerostomia in patients with head and neck cancer: a literature review. Cancer. 2006;107(11):2525–34.

    Article  PubMed  Google Scholar 

  15. Hamlet S, Faull J, Klein B, et al. Mastication and swallowing in patients with postirradiation xerostomia. Int J Radiat Oncol Biol Phys. 1997;37(4):789–96.

    Article  CAS  PubMed  Google Scholar 

  16. Rhodus N, Moller K, Colby S, et al. Articulatory speech performance in patients with salivary gland dysfunction: a pilot study. Quintessence Int. 1995;26(11):805–10.

    CAS  PubMed  Google Scholar 

  17. Roesink JM, Schipper M, Busschers W, et al. A comparison of mean parotid gland dose with measures of parotid gland function after radiotherapy for head-and-neck cancer: implications for future trials. Int J Radiat Oncol Biol Phys. 2005;63(4):1006–9.

    Article  PubMed  Google Scholar 

  18. LENT SOMA tables. Radiotherapy Oncol. 1995;35(1):17–60.

    Article  Google Scholar 

  19. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341–6.

    Article  CAS  PubMed  Google Scholar 

  20. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–81.

    Article  PubMed  Google Scholar 

  21. Common Terminology Criteria for Adverse Events (CTCAE).2009; Version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.

  22. Johnson J, Ferretti G, Nethery W, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med. 1993;329(6):390–5.

    Article  CAS  PubMed  Google Scholar 

  23. Eisbruch A, Kim H, Terrell J, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50(3):695–704.

    Article  CAS  PubMed  Google Scholar 

  24. Ringash J, Warde P, Lockwood G, et al. Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. Int J Radiat Oncol Biol Phys. 2005;61(5):1403–7.

    Article  PubMed  Google Scholar 

  25. Brizel D, Wasserman T, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18(19):3339–45.

    CAS  PubMed  Google Scholar 

  26. Kam M, Leung S, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25(31):4873–9.

    Article  PubMed  Google Scholar 

  27. Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys. 2006;66(4):981–91.

    Article  PubMed  Google Scholar 

  28. Jha N, Seikaly H, McGaw T, et al. Submandibular salivary gland transfer prevents radiation-induced xerostomia. Int J Radiat Oncol Biol Phys. 2000;46(1):7–11.

    Article  CAS  PubMed  Google Scholar 

  29. Seikaly H, Jha N, Harris J, et al. Long-term outcomes of submandibular gland transfer for prevention of postradiation xerostomia. Arch Otolaryngol Head Neck Surg. 2004;130(8):956–61.

    Article  PubMed  Google Scholar 

  30. Jha N, Seikaly H, Harris J, et al. Prevention of radiation induced xerostomia by surgical transfer of submandibular salivary gland into the submental space. Radiother Oncol. 2003;66(3):283–9.

    Article  PubMed  Google Scholar 

  31. Lewin JS. Dysphagia after chemoradiation: prevention and treatment. Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S86–87.

    Article  PubMed  Google Scholar 

  32. Perry AR, Shaw MA. Evaluation of functional outcomes (speech, swallowing and voice) in patients attending speech pathology after head and neck cancer treatment(s): development of a multi-centre database. J Laryngol Otol. 2000;114(8):605–15.

    Article  CAS  PubMed  Google Scholar 

  33. Blood G. Development and assessment of a scale addressing communication needs of patients with laryngectomies. Am J Speech Lang Pathol. 1993;2(3):82–90.

    Article  Google Scholar 

  34. Jacobson B, Johnson A, Grywalski C, et al. The voice handicap index (VHI): development and validation. Am J Speech Lang Pathol. 1997;6(3):66–70.

    Article  Google Scholar 

  35. Llewellyn-Thomas HA, Sutherland HJ, Hogg SA, et al. Linear analogue self-assessment of voice quality in laryngeal cancer. J Chronic Dis. 1984;37(12):917–24.

    Article  CAS  PubMed  Google Scholar 

  36. Ward EC, Bishop B, Frisby J, et al. Swallowing outcomes following laryngectomy and pharyngolaryngectomy. Arch Otolaryngol Head Neck Surg. 2002;128(2):181–6.

    Article  PubMed  Google Scholar 

  37. Lewin J. Speech and swallowing following treatment for oral cancer. In: Werning J, editor. Oral cancer. New York, NY: Thieme Medical Publishers; 2007. p. 304–8.

    Google Scholar 

  38. Karnell LH, Funk GF, Hoffman HT. Assessing head and neck cancer patient outcome domains. Head Neck. 2000;22(1):6–11.

    Article  CAS  PubMed  Google Scholar 

  39. Logemann JA, Pauloski BR, Rademaker AW, et al. Super-supraglottic swallow in irradiated head and neck cancer patients. Head Neck. 1997;19(6):535–40.

    Article  CAS  PubMed  Google Scholar 

  40. List MA, D’Antonio LL, Cella DF, et al. The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale. A study of utility and validity. Cancer. 1996;77(11):2294–301.

    Article  CAS  PubMed  Google Scholar 

  41. Chen AY, Frankowski R, Bishop-Leone J, et al. The development and validation of a dysphagia specific quality-of-life questionnaire for patients with head and neck cancer: The M. D. Anderson dysphagia inventory. Arch Otolaryngol Head Neck Surg. 2001;127(7): 870–6.

    CAS  PubMed  Google Scholar 

  42. McHorney CA, Bricker DE, Kramer AE, et al. The SWAL-QOL outcomes tool for oropharyngeal dysphagia in adults: I. Conceptual foundation and item development. Dysphagia. 2000;15(3):115–21.

    Article  CAS  PubMed  Google Scholar 

  43. McHorney CA, Bricker DE, Robbins J, et al. The SWAL-QOL outcomes tool for oropharyngeal dysphagia in adults: II. Item reduction and preliminary scaling. Dysphagia. 2000;15(3): 122–33.

    Article  CAS  PubMed  Google Scholar 

  44. McHorney CA, Robbins J, Lomax K, et al. The SWAL-QOL and SWAL-CARE outcomes tool for oropharyngeal dysphagia in adults: III. Documentation of reliability and validity. Dysphagia. 2002;17(2):97–114.

    Article  PubMed  Google Scholar 

  45. Logemann JA, Pauloski BR, Rademaker AW, et al. Xerostomia: 12-month changes in saliva production and its relationship to perception and performance of swallow function, oral intake, and diet after chemoradiation. Head Neck. 2003;25(6):432–7.

    Article  PubMed  Google Scholar 

  46. Feinstein AR. Clinimetrics. New Haven, CT: Yale University Press; 1987.

    Google Scholar 

  47. Woodard CA, Chambers LW. Guide to questionnaire construction and question writing. 1st ed. Ottawa: Canadian Public Health Association; 1980.

    Google Scholar 

  48. Cull A, Sprangers M, Bjordal K, et al. EORTC Quality of Life Group Translation Procedure. Brussels: EORTC; 2002.

    Google Scholar 

  49. Reeve B, Hays R, Bjorner J, et al. Psychometric evaluation and calibration of health-related quality of life item banks: Plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care. 2007;45(5 Suppl 1):S22–31.

    Article  PubMed  Google Scholar 

  50. Nunnally JC. Psychometric theory. New York: McGraw Hill; 1978. p. 245–6.

    Google Scholar 

  51. Weiner EA, Stewart BJ. Assessing individuals: psychological and educational tests and measurements. Boston (MA): Little Brown; 1984.

    Google Scholar 

  52. Wright JG. The minimal important difference: who’s to say what is important? J Clin Epidemiol. 1996;49(11):1221–2.

    Article  CAS  PubMed  Google Scholar 

  53. Ringash J, O'Sullivan B, Bezjak A, et al. Interpreting clinically significant changes in patient-reported outcomes. Cancer. 2007; 110(1):196–202.

    Article  PubMed  Google Scholar 

  54. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582–92.

    PubMed  Google Scholar 

  55. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.

    Article  PubMed  Google Scholar 

  56. Schlenk EA, Erlen JA, Dunbar-Jacob J, et al. Health-related quality of life in chronic disorders: A comparison across studies using the MOS SF-36. Qual Life Res. 1998;7(1):57–65.

    Article  CAS  PubMed  Google Scholar 

  57. Johnson JA, Coons SJ. Comparison of the EQ-5D and SF-12 in an adult US sample. Qual Life Res. 1998;7(2):155–66.

    Article  CAS  PubMed  Google Scholar 

  58. Bjordal K, Kaasa S. Psychometric validation of the EORTC Core Quality of Life Questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients. Acta Oncol. 1992;31(3):311–21.

    Article  CAS  PubMed  Google Scholar 

  59. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.

    CAS  PubMed  Google Scholar 

  60. Cella DF. F.A.C.I.T. manual, version 4. Evanston, NY: Centre on Outcomes, Research and Education; 1997.

    Google Scholar 

  61. Stevens CS, Lemon B, Lockwood GA, et al. The development and validation of a quality-of-life questionnaire for head and neck cancer patients with enteral feeding tubes: the QOL-EF. Support Care Cancer. 2011;19(8):1175–82.

    Article  PubMed  Google Scholar 

  62. Ringash J, Bezjak A. A structured review of quality of life instruments for head and neck cancer patients. Head Neck. 2001;23(3):201–13.

    Article  CAS  PubMed  Google Scholar 

  63. Aaronson NK, Ahmedzai S, Bullinger M. The EORTC core quality of life questionnaire: Interim results of an international field study. In: Osoba D, editor. Effect of cancer on quality of life. Boston Mt.: CRC; 1991.

    Google Scholar 

  64. Bjordal K, Ahlner-Elmqvist M, Tollesson E, et al. Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients. EORTC Quality of Life Study Group. Acta Oncol. 1994;33(8):879–85.

    Article  CAS  PubMed  Google Scholar 

  65. Ojo B, Genden EM, Teng MS, et al. A systematic review of head and neck cancer quality of life assessment instruments. Oral Oncol. 2012;48(10):923–37.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Weymuller EA, Yueh B, Deleyiannis FW, et al. Quality of life in patients with head and neck cancer: lessons learned from 549 prospectively evaluated patients. Arch Otolaryngol Head Neck Surg. 2000;126(3):329–35. discussion 335–326.

    Article  CAS  PubMed  Google Scholar 

  67. Hassan SJ, Weymuller Jr EA. Assessment of quality of life in head and neck cancer patients. Head Neck. 1993;15(6):485–96.

    Article  CAS  PubMed  Google Scholar 

  68. Terrell JE, Nanavati KA, Esclamado RM, et al. Head and neck cancer-specific quality of life: instrument validation. Arch Otolaryngol Head Neck Surg. 1997;123(10):1125–32.

    Article  CAS  PubMed  Google Scholar 

  69. Funk G, Karnell L, Christensen A, et al. Comprehensive head and neck oncology health status assessment. Head Neck. 2003;25(7):561–75.

    Article  PubMed  Google Scholar 

  70. Trotti A, Johnson DJ, Gwede C, et al. Development of a head and neck companion module for the quality of life-radiation therapy instrument (QOL-RTI). Int J Radiat Oncol Biol Phys. 1998; 42(2):257–61.

    Article  CAS  PubMed  Google Scholar 

  71. Browman GP, Levine MN, Hodson DI, et al. The Head and Neck Radiotherapy Questionnaire: A morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer. J Clin Oncol. 1993;11(5):863–72.

    CAS  PubMed  Google Scholar 

  72. Sprangers MAG, Schwartz CE. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med. 1999;48:1507–15.

    Article  CAS  PubMed  Google Scholar 

  73. Holzner B, Kemmler G, Cella D, et al. Normative data for functional assessment of cancer therapy—general scale and its use for the interpretation of quality of life scores in cancer survivors. Acta Oncol. 2004;43(2):153–60.

    Article  PubMed  Google Scholar 

  74. Guren MG, Dueland S, Skovlund E, et al. Quality of life during radiotherapy for rectal cancer. Eur J Cancer. 2003;39(5):587–94.

    Article  CAS  PubMed  Google Scholar 

  75. Osoba D, Zee B. Completion rates in health-related quality-of-life assessment: approach of the National Cancer Institute of Canada Clinical Trials Group. Stat Med. 1998;17(5–7):603–12.

    Article  CAS  PubMed  Google Scholar 

  76. Osoba D, Bezjak A, Brundage M, et al. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer. 2005;41(2):280–7.

    Article  PubMed  Google Scholar 

  77. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318(26):1728–33.

    Article  CAS  PubMed  Google Scholar 

  78. Davis D, Evans M, Jadad A, et al. The case for knowledge translation: shortening the journey from evidence to effect. BMJ. 2003;327(7405):33–5.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Bezjak A, Ng P, Skeel R, et al. Oncologists’ use of quality of life information: results of a survey of Eastern Cooperative Oncology Group physicians. Qual Life Res. 2001;10(1):1–13.

    Article  CAS  PubMed  Google Scholar 

  80. Guyatt GH, Naylor CD, Juniper E, et al. Users’ guides to the medical literature. XII. How to use articles about health-related quality of life. Evidence-Based Medicine Working Group. JAMA. 1997;277(15):1232–7.

    Article  CAS  PubMed  Google Scholar 

  81. Sprangers MA, Moinpour CM, Moynihan TJ, et al. Assessing meaningful change in quality of life over time: a users’ guide for clinicians. Mayo Clin Proc. 2002;77(6):561–71.

    Article  PubMed  Google Scholar 

  82. Brundage M, Blazeby J, Revicki D, et al. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res. 2013;22(6):1161–75.

    Article  PubMed  Google Scholar 

  83. Brundage M, Bass B, Davidson J, et al. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res. 2011;20(5):653–64.

    Article  PubMed  Google Scholar 

  84. Rouette J, Blazeby J, King M, et al. Integrating health-related quality of life findings from randomized clinical trials into practice: an international study of oncologists’ perspectives. Qual Life Res. 2015;24:1317–25.

    Article  PubMed  Google Scholar 

  85. Klein J, Livergant J, Ringash J. Health related quality of life in head and neck cancer treated with radiation therapy with or without chemotherapy: a systematic review. Oral Oncol. 2014;50(4):254–62.

    Article  PubMed  Google Scholar 

  86. Rathod S, Livergant J, J. K, et al. Health related quality of life in head and neck cancer treated with surgery with or without adjuvant (chemo)radiotherapy: A systematic review. Oral Oncal. 2015;51(10):888–900.

    Google Scholar 

  87. Curran D, Giralt J, Harari P, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol. 2007;25(16):2191–7.

    Article  CAS  PubMed  Google Scholar 

  88. Rathod S, Gupta T, Ghosh-Laskar S, et al. Quality-of-life (QOL) outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with intensity-modulated radiation therapy (IMRT) compared to three-dimensional conformal radiotherapy (3D-CRT): evidence from a prospective randomized study. Oral Oncol. 2013;49(6):634–42.

    Article  PubMed  Google Scholar 

  89. Bottomley A, Tridello G, Coens C, et al. An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group. Cancer. 2014;120(3):390–8.

    Article  PubMed  Google Scholar 

  90. Ackerstaff AH, Rasch CR, Balm AJ, et al. Five-year quality of life results of the randomized clinical phase III (RADPLAT) trial, comparing concomitant intra-arterial versus intravenous chemoradiotherapy in locally advanced head and neck cancer. Head Neck. 2012;34(7):974–80.

    Article  PubMed  Google Scholar 

  91. van Herpen CM, Mauer ME, Mesia R, et al. Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323). Br J Cancer. 2010;103(8):1173–81.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  92. Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al. The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer. 2001;37(1):23–31.

    Article  CAS  PubMed  Google Scholar 

  93. Castro DJ, Sridhar KS, Garewal HS, et al. Intratumoral cisplatin/epinephrine gel in advanced head and neck cancer: a multicenter, randomized, double-blind, phase III study in North America. Head Neck. 2003;25(9):717–31.

    Article  PubMed  Google Scholar 

  94. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib 250 compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27(11):1864–71.

    Article  CAS  PubMed  Google Scholar 

  95. van der Meulen IC, May AM, de Leeuw JR, et al. Long-term effect of a nurse-led psychosocial intervention on health-related quality of life in patients with head and neck cancer: a randomised controlled trial. Br J Cancer. 2014;110(3):593–601.

    Article  PubMed  Google Scholar 

  96. Antunes HS, Herchenhorn D, Small IA, et al. Phase III trial of low-level laser therapy to prevent oral mucositis in head and neck cancer patients treated with concurrent chemoradiation. Radiother Oncol. 2013;109(2):297–302.

    Article  PubMed  Google Scholar 

  97. Gautam AP, Fernandes DJ, Vidyasagar MS, et al. Effect of low-level laser therapy on patient reported measures of oral mucositis and quality of life in head and neck cancer patients receiving chemoradiotherapy—a randomized controlled trial. Support Care Cancer. 2013;21(5):1421–8.

    Article  PubMed  Google Scholar 

  98. Oton-Leite AF, Correa de Castro AC, Morais MO, et al. Effect of intraoral low-level laser therapy on quality of life of patients with head and neck cancer undergoing radiotherapy. Head Neck. 2012;34(3):398–404.

    Article  PubMed  Google Scholar 

  99. Silander E, Nyman J, Bove M, et al. Impact of prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients with head and neck cancer: a randomized study. Head Neck. 2012;34(1):1–9.

    Article  PubMed  Google Scholar 

  100. Fisher J, Scott C, Scarantino CW, et al. Phase III quality-of-life study results: impact on patients’ quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer—RTOG 97–09. Int J Radiat Oncol Biol Phys. 2003;56(3):832–6.

    Article  PubMed  Google Scholar 

  101. Duncan GG, Epstein JB, Tu D, et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck. 2005;27(5):421–8.

    Article  PubMed  Google Scholar 

  102. Elliott EA, Wright JR, Swann RS, et al. Phase III Trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99–13. J Clin Oncol. 2006;24(13):2092–7.

    Article  CAS  PubMed  Google Scholar 

  103. Hoffman KE, Pugh SL, James JL, et al. The impact of concurrent granulocyte-macrophage colony-stimulating factor on quality of life in head and neck cancer patients: results of the randomized, placebo-controlled Radiation Therapy Oncology Group 9901 trial. Qual Life Res. 2014;23(6):1841–58.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Rogers LQ, Anton PM, Fogleman A, et al. Pilot, randomized trial of resistance exercise during radiation therapy for head and neck cancer. Head Neck. 2013;35(8):1178–88.

    Article  PubMed  Google Scholar 

  105. Samuel SR, Maiya GA, Babu AS, et al. Effect of exercise training on functional capacity & quality of life in head & neck cancer patients receiving chemoradiotherapy. Indian J Med Res. 2013;137(3):515–20.

    PubMed  PubMed Central  Google Scholar 

  106. Lonbro S, Dalgas U, Primdahl H, et al. Progressive resistance training rebuilds lean body mass in head and neck cancer patients after radiotherapy—results from the randomized DAHANCA 25B trial. Radiother Oncol. 2013;108(2):314–9.

    Article  PubMed  Google Scholar 

  107. Goldstein DP, Hynds Karnell L, Christensen AJ, et al. Health-related quality of life profiles based on survivorship status for head and neck cancer patients. Head Neck. 2007;29(3): 221–9.

    Article  PubMed  Google Scholar 

  108. Siddiqui F, Pajak T, Watkins-Bruner D, et al. Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis. Int J Radiat Oncol Biol Phys. 2008;70(2):353–60.

    Article  PubMed  Google Scholar 

  109. Ringash J, Fisher R, Peters L, et al. Effect of P16 status on the quality of life experience during chemoradiation for locally advanced oropharyngeal cancer: a sub-study of TROG 02.02 (HeadSTART). Radiat Oncol Biol Phys. 2016; doi:http:dx.doi.org/10.1016/jiijrobp.2016.03.017. Published online March 22,2016.

    Google Scholar 

  110. Guyatt GH, Ferrans CE, Halyard MY, et al. Exploration of the value of health-related quality-of-life information from clinical research and into clinical practice. Mayo Clin Proc. 2007;82(10): 1229–39.

    Article  PubMed  Google Scholar 

  111. Velikova G, Booth L, Smith A, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004;22(4):714–24.

    Article  PubMed  Google Scholar 

  112. Detmar S, Muller M, Schornagel J, et al. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA. 2002;288(23):3027–34.

    Article  PubMed  Google Scholar 

  113. Ringash J, Macedo A, Li M, et al. Routine clinical quality of life measurement for head and neck cancer patients: Example from a Province-wide Oncology Initiative [abstract]. Qual Life Res. 2014;23(124):55–6.

    Google Scholar 

  114. Jensen RE, Snyder CF, Abernethy AP, et al. Review of electronic patient-reported outcomes systems used in cancer clinical care. J Oncol Pract. 2014;10(4):e215–222.

    Article  PubMed  Google Scholar 

  115. Hoffman HT, Karnell LH, Funk GF, et al. The National Cancer Data Base report on cancer of the head and neck. Arch Otolaryngol Head Neck Surg. 1998;124(9):951–62.

    Article  CAS  PubMed  Google Scholar 

  116. Sehlen S, Hollenhorst H, Lenk M, et al. Only sociodemographic variables predict quality of life after radiography in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;52(3): 779–83.

    Article  PubMed  Google Scholar 

  117. Shi W, Kato H, Perez-Ordonez B, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol. 2009;27(36):6213–21.

    Article  PubMed  Google Scholar 

  118. Ader DNS. Developing the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care. 2007; 45(1):S1–2.

    Article  Google Scholar 

  119. Assessment Center. What is assessment center. http://www.assessmentcenter.net/ac1/. Accessed January 19 2015.

Download references

Author information

Authors and Affiliations

  1. The University of Toronto, Toronto, ON, Canada

    Jolie Ringash BSc, MD, MSc

  2. Department of Radiation Oncology, The Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, Canada, M5G1M9

    Jolie Ringash BSc, MD, MSc

Authors
  1. Jolie Ringash BSc, MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jolie Ringash BSc, MD, MSc .

Editor information

Editors and Affiliations

  1. Department of Radio-Oncology, Genolier Swiss Medical Network, Genolier, Switzerland

    Jacques Bernier

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Ringash, J. (2016). Quality of Life in Head and Neck Cancer Patients. In: Bernier, J. (eds) Head and Neck Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-27601-4_49

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-27601-4_49

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-27599-4

  • Online ISBN: 978-3-319-27601-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation